Company Overview of Xellia Pharmaceuticals AS
Xellia Pharmaceuticals AS, a specialty pharmaceutical company, develops, manufactures, and supplies fermented and semi-synthetic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company focuses on anti-infective treatments against serious and often life-threatening infections. Its APIs and FDFs include antibacterial agents treating gram-positive and gram-negative infections, antifungal agents, corticosteroids, and biphosphonhates. The company also develops device delivery systems, such as metered dose pumps for topical formulations, ready to use injectable bag systems for use in the hospital setting, and aqueous droplet inhalation devices for out-patient use. In...
Founded in 1994
Key Executives for Xellia Pharmaceuticals AS
Chief Financial Officer and Vice President
Chief Legal Officer and Vice President
Head of Production for Oslo and Operations Director of Oslo
Head of Production for Taizhou and Operations General Manager for Taizhou
Compensation as of Fiscal Year 2012.
Xellia Pharmaceuticals AS Key Developments
3i Group Reportedly In Advanced Talks For Sale Of Xellia
Apr 25 13
3i Group plc (LSE:III) is in advanced negotiations to sell Xellia Pharmaceuticals AS, reported Reuters citing two people familiar with the matter. The report added that the sale of Xellia could fetch €750 million. Linklaters is acting as legal adviser to 3i. A 3i spokesperson was not available for comment. Linklaters did not immediately return a request for comment.
Xellia Pharmaceuticals AS Enters Four Year Collaboration with SINTEF Materials and Chemistry and Statens Serum Institut
Feb 26 13
Xellia Pharmaceuticals announced that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria. This four year development project at Xellia is a collaboration with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen). The project is being supported by a $3 million grant from the Research Council of Norway (NFR). The project also includes contributions from laboratories across Europe. Xellia is aiming to develop new antibiotics that target Gram-negative bacterial infections, caused by, for example Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species. Severe sepsis and septic shock due to such infections take up to 135,000 lives each year in Europe and 215,000 in USA. Resistance to existing antibiotics has become a major healthcare issue worldwide. In the EU alone, infections due to serious hospital-based MDR infections have been reported to cost between EUR 28,500 (in hospital units and ICUs) and EUR 70,100 (in MDR ICUs) per surviving patient. Recently, pan-drug resistant (PDR) and even so-called extensively drug resistant (XDR) Gram-negative bacteria have started to appear, taking the treatment situation to a critical point. The lack of novel antibiotics is significantly compromising the survival and recovery of patients suffering from these infections. At present, only two antibiotic subclasses are still available to treat XDR infections, polymyxins and tigecycline.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries